CUV 1.61% $14.68 clinuvel pharmaceuticals limited

Germany's Biofrontera expects to have its actinic keratosis drug...

  1. 648 Posts.
    Germany's Biofrontera expects to have its actinic keratosis drug approved by the EMEA in 2011 (their drug is not a prophylactic drug). Their drug completed Phase III earlier this year.
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.